Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs.

BACKGROUND The lysosomal cysteine proteases of the papain family are some of the best studied proteolytic enzymes. Small-molecule inhibitors and fluorogenic substrate mimics have been used to probe the physiological roles of these proteases. A high degree of homology between family members and overlap in substrate specificity have made elucidating individual protease function, expression and activity difficult. RESULTS Using peptide vinyl sulfones and epoxide as templates, we have generated probes that can be tagged with radioactive iodine. The resulting compounds covalently label various cathepsins and several unidentified polypeptides likely to be proteases. MB-074 was found to be a highly selective probe of cathepsin B activity. Probes that labeled several cathepsins were used to examine the specificity and cell permeability of the CA-074 family of inhibitors. Although CA-074 reportedly acts in vivo, we find it is unable to penetrate cells. Esterifying CA-074 resulted in a cell-permeable inhibitor with dramatically reduced activity and specificity for cathepsin B. The probes were also used to monitor protease activity in primary human tumor tissue and cells derived from human placenta. CONCLUSIONS We have generated a highly selective cathepsin B probe and several less specific reagents for the study of cathepsin biology. The reagents have several advantages over commonly used fluorogenic substrates, allowing inhibitor targets to be identified in a pool of total cellular enzymes. We have used the probes to show that cathepsin activity is regulated in tumor tissues and during differentiation of placental-derived cytotrophoblasts to invasive cells required for establishing blood circulation in a developing embryo.

[1]  N. Katunuma,et al.  Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivo , 1991, FEBS letters.

[2]  R. Mason,et al.  Control of breast tumor cell growth using a targeted cysteine protease inhibitor. , 1998, Cancer research.

[3]  D. Rich,et al.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.

[4]  K. Lim,et al.  Integrin switching regulates normal trophoblast invasion. , 1994, Development.

[5]  William N. Kelley,et al.  Textbook of rheumatology , 1985 .

[6]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[7]  C. Damsky,et al.  Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors. , 1998, Current opinion in cell biology.

[8]  T. Schirmeister,et al.  Cysteine Proteases and Their Inhibitors. , 1997, Chemical reviews.

[9]  N. Katunuma,et al.  Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. , 1998, Journal of immunology.

[10]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[11]  H. Mcdevitt,et al.  The LMP antigens: a stable MHC-controlled multisubunit protein complex. , 1986, Human immunology.

[12]  Z. Werb,et al.  92-kD type IV collagenase mediates invasion of human cytotrophoblasts , 1991, The Journal of cell biology.

[13]  H. Chapman,et al.  Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.

[14]  A. Barrett,et al.  CA074 methyl ester: a proinhibitor for intracellular cathepsin B. , 1992, Archives of biochemistry and biophysics.

[15]  D. Rich,et al.  Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. , 1996, Journal of medicinal chemistry.

[16]  H. Chapman,et al.  Endosomal proteolysis and MHC class II function. , 1998, Current opinion in immunology.

[17]  R. Mason,et al.  Quantification of cathepsins B and L in cells. , 1998, The Biochemical journal.

[18]  A. Goldberg,et al.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Sunny Shin,et al.  Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. , 1998, Chemistry & biology.

[20]  J. Palmer,et al.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.

[21]  R. Mason,et al.  Design of a transferrin-proteinase inhibitor conjugate to probe for active cysteine proteinases in endosomes. , 1998, The Biochemical journal.

[22]  Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins , 1989 .

[23]  E. Dejana,et al.  Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? , 1997, The Journal of clinical investigation.

[24]  G. Zhang,et al.  Adhesive and degradative properties of human placental cytotrophoblast cells in vitro , 1989, The Journal of cell biology.

[25]  I. Kuntz,et al.  Inclusion of Solvation in Ligand Binding Free Energy Calculations Using the Generalized-Born Model , 1999 .

[26]  N. Katunuma,et al.  Abnormal expression of lysosomal cysteine proteinases in muscle wasting diseases. , 1987, Reviews of physiology, biochemistry and pharmacology.

[27]  R. Ménard,et al.  Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B. , 1993, Journal of medicinal chemistry.

[28]  N. Katunuma,et al.  Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. , 1998, Advances in enzyme regulation.

[29]  R. Huber,et al.  Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. , 1995, Biochemistry.

[30]  E. Shaw,et al.  The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor. , 1989, The Biochemical journal.

[31]  R. Mitchell,et al.  Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.

[32]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[33]  T Vernet,et al.  Role of the Occluding Loop in Cathepsin B Activity* , 1997, The Journal of Biological Chemistry.

[34]  E. Shaw,et al.  Cysteinyl proteinases and their selective inactivation. , 1990, Advances in enzymology and related areas of molecular biology.

[35]  M. Murata,et al.  Novel epoxysuccinyl peptides Selective inhibitors of cathepsin B, in vitro , 1991, FEBS letters.